Maupas-Schwalm Françoise, Robinet Catherine, Augé Nathalie, Thiers Jean-Claude, Garcia Virginie, Cambus Jean-Pierre, Salvayre Robert, Nègre-Salvayre Anne
Institut National de la Santé et de la Recherche Médicale U466, IFR31, Centre Hospitalier Universitaire Rangueil, Toulouse, France.
Cancer Res. 2005 Jan 15;65(2):526-32.
Besides its involvement in clot lysis, the plasminogen activator (PA) system elicits various cellular responses involved in cell migration, adhesion, and proliferation and plays a key role in the progression of cancers. beta-Catenin interacts with E-cadherins and functions as transcriptional coactivator of the Wnt-signaling pathway, which is implicated in tumor formation when aberrantly activated. We report that tissue-type plasminogen activator (tPA) elicited tyrosine phosphorylation and cytosolic accumulation of an active (non-serine-threonin phosphorylated, nonubiquitinated) form of beta-catenin in ECV304 carcinoma cells. tPA-dependent beta-catenin activation is mediated through epidermal growth factor receptor (EGFR) transactivation (via Src), suggested by the inhibitory effects of AG1478 and PP2 (specific inhibitors of EGFR and Src, respectively) and by the lack of beta-catenin activation in EGFR-negative B82 fibroblasts. EGFR phosphorylation and beta-catenin activation were inhibited by plasminogen activator inhibitor 1 and pertussis toxin, two inhibitors of the urokinase-type plasminogen activator (uPA)/uPA receptor system. beta-Catenin activation was correlated with the phosphorylation of glycogen synthase kinase-3beta through a phosphatidylinositol 3-kinase/Akt-dependent mechanism. Gel shift experiments revealed the activation of beta-catenin/T-cell-specific transcription factor (Tcf)/lymphoid enhancer factor-1 (Lef) transcriptional complex, evidenced by an increased binding of nuclear extracts to oligonucleotides containing the cyclin D1 Lef/Tcf site. beta-Catenin silencing through small interfering RNA and antisense oligonucleotides inhibited both the tPA-mediated cyclin D1 expression and cell proliferation. A similar activation of the beta-catenin pathway was triggered by amino-terminal fragment, the NH(2)-terminal catalytically inactive fragment of tPA, thus suggesting that this effect was independent of the proteolytic activity of plasminogen activators. In conclusion, the beta-catenin/Lef/Tcf pathway is activated by tPA and is involved in cell cycle progression and proliferation.
除了参与血栓溶解外,纤溶酶原激活剂(PA)系统还引发多种参与细胞迁移、黏附和增殖的细胞反应,并在癌症进展中起关键作用。β-连环蛋白与E-钙黏蛋白相互作用,并作为Wnt信号通路的转录共激活因子发挥作用,该信号通路异常激活时与肿瘤形成有关。我们报道,组织型纤溶酶原激活剂(tPA)在ECV304癌细胞中引发了活性(非丝氨酸-苏氨酸磷酸化、非泛素化)形式的β-连环蛋白的酪氨酸磷酸化和胞质积累。AG1478和PP2(分别为EGFR和Src的特异性抑制剂)的抑制作用以及EGFR阴性的B82成纤维细胞中β-连环蛋白未被激活,提示tPA依赖的β-连环蛋白激活是通过表皮生长因子受体(EGFR)转激活(通过Src)介导的。纤溶酶原激活剂抑制剂1和百日咳毒素(两种尿激酶型纤溶酶原激活剂(uPA)/uPA受体系统的抑制剂)抑制了EGFR磷酸化和β-连环蛋白激活。β-连环蛋白激活通过磷脂酰肌醇3-激酶/Akt依赖机制与糖原合酶激酶-3β的磷酸化相关。凝胶迁移实验揭示了β-连环蛋白/T细胞特异性转录因子(Tcf)/淋巴细胞增强因子-1(Lef)转录复合物的激活,核提取物与含有细胞周期蛋白D1 Lef/Tcf位点的寡核苷酸结合增加证明了这一点。通过小干扰RNA和反义寡核苷酸使β-连环蛋白沉默抑制了tPA介导的细胞周期蛋白D1表达和细胞增殖。tPA的氨基末端片段(tPA的NH2-末端催化无活性片段)引发了类似的β-连环蛋白通路激活,因此提示这种效应与纤溶酶原激活剂的蛋白水解活性无关。总之,β-连环蛋白/Lef/Tcf通路被tPA激活,并参与细胞周期进程和增殖。